Cargando…

Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study

BACKGROUND AND OBJECTIVES: Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our objectives were to (1) determine diagnostic performances of CSF KFLC, KFL...

Descripción completa

Detalles Bibliográficos
Autores principales: Levraut, Michael, Laurent-Chabalier, Sabine, Ayrignac, Xavier, Bigaut, Kévin, Rival, Manon, Squalli, Sanae, Zéphir, Hélène, Alberto, Tifanie, Pekar, Jean-David, Ciron, Jonathan, Biotti, Damien, Puissant-Lubrano, Bénédicte, Camdessanché, Jean-Philippe, Tholance, Yannick, Casez, Olivier, Toussaint, Bertrand, Marion, Jeanne, Moreau, Thibault, Lakomy, Daniela, Thomasset, Audrey, Maillart, Elisabeth, Sterlin, Delphine, Maurousset, Aude, Rocher, Auriane, Laplaud, David Axel, Bigot-Corbel, Edith, Bertho, Pierre-Olivier, Pelletier, Jean, Boucraut, Joseph, Labauge, Pierre, Vincent, Thierry, De Sèze, Jérôme, Jahn, Isabelle, Seitz-Polski, Barbara, Thouvenot, Eric, Lebrun-Frenay, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663206/
https://www.ncbi.nlm.nih.gov/pubmed/36376096
http://dx.doi.org/10.1212/NXI.0000000000200049
_version_ 1784830822027624448
author Levraut, Michael
Laurent-Chabalier, Sabine
Ayrignac, Xavier
Bigaut, Kévin
Rival, Manon
Squalli, Sanae
Zéphir, Hélène
Alberto, Tifanie
Pekar, Jean-David
Ciron, Jonathan
Biotti, Damien
Puissant-Lubrano, Bénédicte
Camdessanché, Jean-Philippe
Tholance, Yannick
Casez, Olivier
Toussaint, Bertrand
Marion, Jeanne
Moreau, Thibault
Lakomy, Daniela
Thomasset, Audrey
Maillart, Elisabeth
Sterlin, Delphine
Maurousset, Aude
Rocher, Auriane
Laplaud, David Axel
Bigot-Corbel, Edith
Bertho, Pierre-Olivier
Pelletier, Jean
Boucraut, Joseph
Labauge, Pierre
Vincent, Thierry
De Sèze, Jérôme
Jahn, Isabelle
Seitz-Polski, Barbara
Thouvenot, Eric
Lebrun-Frenay, Christine
author_facet Levraut, Michael
Laurent-Chabalier, Sabine
Ayrignac, Xavier
Bigaut, Kévin
Rival, Manon
Squalli, Sanae
Zéphir, Hélène
Alberto, Tifanie
Pekar, Jean-David
Ciron, Jonathan
Biotti, Damien
Puissant-Lubrano, Bénédicte
Camdessanché, Jean-Philippe
Tholance, Yannick
Casez, Olivier
Toussaint, Bertrand
Marion, Jeanne
Moreau, Thibault
Lakomy, Daniela
Thomasset, Audrey
Maillart, Elisabeth
Sterlin, Delphine
Maurousset, Aude
Rocher, Auriane
Laplaud, David Axel
Bigot-Corbel, Edith
Bertho, Pierre-Olivier
Pelletier, Jean
Boucraut, Joseph
Labauge, Pierre
Vincent, Thierry
De Sèze, Jérôme
Jahn, Isabelle
Seitz-Polski, Barbara
Thouvenot, Eric
Lebrun-Frenay, Christine
author_sort Levraut, Michael
collection PubMed
description BACKGROUND AND OBJECTIVES: Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our objectives were to (1) determine diagnostic performances of CSF KFLC, KFLC index, and KFLC intrathecal fraction (IF) threshold values that allow us to separate MS from different CNS disorder control populations and compare them with oligoclonal bands' (OCB) performances and (2) to identify independent factors associated with KFLC quantification in MS. METHODS: We conducted a retrospective multicenter study involving 13 French MS centers. Patients were included if they had a noninfectious and nontumoral CNS disorder, eligible data concerning CSF and serum KFLC, albumin, and OCB. Patients were classified into 4 groups according to their diagnosis: MS, clinically isolated syndrome (CIS), other inflammatory CNS disorders (OIND), and noninflammatory CNS disorder controls (NINDC). RESULTS: One thousand six hundred twenty-one patients were analyzed (675 MS, 90 CIS, 297 OIND, and 559 NINDC). KFLC index and KFLC IF had similar performances in diagnosing MS from nonselected controls and OIND (p = 0.123 and p = 0.991 for area under the curve [AUC] comparisons) and performed better than CSF KFLC (p < 0.001 for all AUC comparisons). A KFLC index of 8.92 best separated MS/CIS from the entire nonselected control population, with better performances than OCB (p < 0.001 for AUC comparison). A KFLC index of 11.56 best separated MS from OIND, with similar performances than OCB (p = 0.065). In the multivariate analysis model, female gender (p = 0.003), young age (p = 0.013), and evidence of disease activity (p < 0.001) were independent factors associated with high KFLC index values in patients with MS, whereas MS phenotype, immune-modifying treatment use at sampling, and the FLC analyzer type did not influence KFLC index. DISCUSSION: KFLC biomarkers are efficient tools to separate patients with MS from controls, even when compared with other patients with CNS autoimmune disorder. Given these results, we suggest using KFLC index or KFLC IF as a criterion to diagnose MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that KFLC index or IF can be used to differentiate patients with MS from nonselected controls and from patients with other autoimmune CNS disorders.
format Online
Article
Text
id pubmed-9663206
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96632062022-11-14 Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study Levraut, Michael Laurent-Chabalier, Sabine Ayrignac, Xavier Bigaut, Kévin Rival, Manon Squalli, Sanae Zéphir, Hélène Alberto, Tifanie Pekar, Jean-David Ciron, Jonathan Biotti, Damien Puissant-Lubrano, Bénédicte Camdessanché, Jean-Philippe Tholance, Yannick Casez, Olivier Toussaint, Bertrand Marion, Jeanne Moreau, Thibault Lakomy, Daniela Thomasset, Audrey Maillart, Elisabeth Sterlin, Delphine Maurousset, Aude Rocher, Auriane Laplaud, David Axel Bigot-Corbel, Edith Bertho, Pierre-Olivier Pelletier, Jean Boucraut, Joseph Labauge, Pierre Vincent, Thierry De Sèze, Jérôme Jahn, Isabelle Seitz-Polski, Barbara Thouvenot, Eric Lebrun-Frenay, Christine Neurol Neuroimmunol Neuroinflamm Research Article BACKGROUND AND OBJECTIVES: Kappa free light chains (KFLC) seem to efficiently diagnose MS. However, extensive cohort studies are lacking to establish consensus cut-offs, notably to rule out non-MS autoimmune CNS disorders. Our objectives were to (1) determine diagnostic performances of CSF KFLC, KFLC index, and KFLC intrathecal fraction (IF) threshold values that allow us to separate MS from different CNS disorder control populations and compare them with oligoclonal bands' (OCB) performances and (2) to identify independent factors associated with KFLC quantification in MS. METHODS: We conducted a retrospective multicenter study involving 13 French MS centers. Patients were included if they had a noninfectious and nontumoral CNS disorder, eligible data concerning CSF and serum KFLC, albumin, and OCB. Patients were classified into 4 groups according to their diagnosis: MS, clinically isolated syndrome (CIS), other inflammatory CNS disorders (OIND), and noninflammatory CNS disorder controls (NINDC). RESULTS: One thousand six hundred twenty-one patients were analyzed (675 MS, 90 CIS, 297 OIND, and 559 NINDC). KFLC index and KFLC IF had similar performances in diagnosing MS from nonselected controls and OIND (p = 0.123 and p = 0.991 for area under the curve [AUC] comparisons) and performed better than CSF KFLC (p < 0.001 for all AUC comparisons). A KFLC index of 8.92 best separated MS/CIS from the entire nonselected control population, with better performances than OCB (p < 0.001 for AUC comparison). A KFLC index of 11.56 best separated MS from OIND, with similar performances than OCB (p = 0.065). In the multivariate analysis model, female gender (p = 0.003), young age (p = 0.013), and evidence of disease activity (p < 0.001) were independent factors associated with high KFLC index values in patients with MS, whereas MS phenotype, immune-modifying treatment use at sampling, and the FLC analyzer type did not influence KFLC index. DISCUSSION: KFLC biomarkers are efficient tools to separate patients with MS from controls, even when compared with other patients with CNS autoimmune disorder. Given these results, we suggest using KFLC index or KFLC IF as a criterion to diagnose MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that KFLC index or IF can be used to differentiate patients with MS from nonselected controls and from patients with other autoimmune CNS disorders. Lippincott Williams & Wilkins 2022-11-14 /pmc/articles/PMC9663206/ /pubmed/36376096 http://dx.doi.org/10.1212/NXI.0000000000200049 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Research Article
Levraut, Michael
Laurent-Chabalier, Sabine
Ayrignac, Xavier
Bigaut, Kévin
Rival, Manon
Squalli, Sanae
Zéphir, Hélène
Alberto, Tifanie
Pekar, Jean-David
Ciron, Jonathan
Biotti, Damien
Puissant-Lubrano, Bénédicte
Camdessanché, Jean-Philippe
Tholance, Yannick
Casez, Olivier
Toussaint, Bertrand
Marion, Jeanne
Moreau, Thibault
Lakomy, Daniela
Thomasset, Audrey
Maillart, Elisabeth
Sterlin, Delphine
Maurousset, Aude
Rocher, Auriane
Laplaud, David Axel
Bigot-Corbel, Edith
Bertho, Pierre-Olivier
Pelletier, Jean
Boucraut, Joseph
Labauge, Pierre
Vincent, Thierry
De Sèze, Jérôme
Jahn, Isabelle
Seitz-Polski, Barbara
Thouvenot, Eric
Lebrun-Frenay, Christine
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title_full Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title_fullStr Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title_full_unstemmed Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title_short Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
title_sort kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: a large multicenter cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663206/
https://www.ncbi.nlm.nih.gov/pubmed/36376096
http://dx.doi.org/10.1212/NXI.0000000000200049
work_keys_str_mv AT levrautmichael kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT laurentchabaliersabine kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT ayrignacxavier kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT bigautkevin kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT rivalmanon kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT squallisanae kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT zephirhelene kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT albertotifanie kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT pekarjeandavid kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT cironjonathan kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT biottidamien kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT puissantlubranobenedicte kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT camdessanchejeanphilippe kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT tholanceyannick kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT casezolivier kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT toussaintbertrand kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT marionjeanne kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT moreauthibault kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT lakomydaniela kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT thomassetaudrey kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT maillartelisabeth kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT sterlindelphine kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT mauroussetaude kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT rocherauriane kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT laplauddavidaxel kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT bigotcorbeledith kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT berthopierreolivier kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT pelletierjean kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT boucrautjoseph kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT labaugepierre kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT vincentthierry kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT desezejerome kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT jahnisabelle kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT seitzpolskibarbara kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT thouvenoteric kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy
AT lebrunfrenaychristine kappafreelightchainbiomarkersareefficientforthediagnosisofmultiplesclerosisalargemulticentercohortstudy